Looking for our Business Solutions? Click here:CloudQuote APIsContact Us

Articles from Revelation Biosciences

Revelation Biosciences Announces Accelerated Gemini Development Plan and Strategic Partnership Initiatives
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative therapies designed to rebalance the body’s inflammatory response, today announced a strategic shift designed to accelerate development of Gemini, its proprietary therapeutic candidate designed to restore the body’s natural inflammatory balance through multiple biological pathways. The strategy includes advancing a streamlined Phase 2a clinical study in patients with stage 2 or 3 acute kidney injury (AKI) to generate safety and efficacy data more rapidly and at substantially lower cost, while pursuing strategic partnerships and licensing opportunities to support Gemini’s development and expand its commercial potential.
By Revelation Biosciences · Via Business Wire · November 16, 2026